published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists". Obesity is a multifaceted disease with increasing prevalence and profound ...

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent results for mood disorders.

arthritic disorders. HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, ...

A New Tool for Researchers Developing Dual- and Triple-Agonist Therapies for Obesity, Diabetes, and Other Metabolic ... its already popular Glucagon-like Peptide-1 Receptor (GLP-1R) and Gastric ...

As the body of research expands on the potential of glucagon-like peptide ... use disorder (AUD), published in Addiction last October, researchers reported that GLP-1 receptor agonists and similar ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 study suggesting a potential role for GLP-1 agonists in PD.

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...